# **Special Issue**

# Recent Advances in Antimicrobial Nano-Drug Delivery Systems

## Message from the Guest Editor

The widespread utilization of antimicrobial compounds throughout recent years has played a role in the spread of multi-drug-resistant microorganisms. According to a recent World Health Organization report, grappling with antibacterial (ATB) drug resistance and the creation of durable ATBs poses a substantial challenge. As pathogens swiftly adapt and evolve through various mechanisms; conventional ATBs frequently lead to only temporarily effective or ineffective treatments. Consequently, there is a growing interest in novel therapeutic approaches, such as those based on nanodrug delivery systems (NDDS) and nanoparticles with intrinsic antimicrobial activity, due to their potential to enhance drug bioavailability, improve targeting, and overcome the resistance mechanisms. These can include nanoemulsions, liposomes, nanostructured lipid carriers, solid lipid nanoparticles, polymeric nanoparticles, metal nanoparticles, and others. Acknowledging the importance of this subject matter, this Special Issue endeavors to curate the recent strides in nanomedicine specifically tailored to the maladies caused by microorganisms.

## **Guest Editor**

Prof. Dr. Luís Alexandre Muehlmann Faculty of Ceilândia, University of Brasília, Brasília 70910-900, Brazil

## Deadline for manuscript submissions

closed (20 November 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/192598

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

